Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Rick_Klausner
|
| gptkbp:collaboratesWith |
gptkb:Fred_Hutchinson_Cancer_Research_Center
GlaxoSmithKline |
| gptkbp:focusesOn |
gptkb:cancer
immunotherapy gene therapy |
| gptkbp:foundedYear |
2018
|
| gptkbp:founder |
gptkb:Rick_Klausner
|
| gptkbp:headquartersLocation |
gptkb:South_San_Francisco,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Lyell Immunopharma
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
gptkb:LYL132
gptkb:LYL797 LYL845 |
| gptkbp:publiclyTraded |
yes
|
| gptkbp:specializesIn |
T-cell therapies
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:LYEL
|
| gptkbp:website |
https://www.lyell.com/
|
| gptkbp:bfsParent |
gptkb:Hans_Bishop
gptkb:Richard_Klausner |
| gptkbp:bfsLayer |
6
|